Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial.
Neuropsychopharmacology reports（2023）
摘要
Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety.
更多查看译文
关键词
COVID-19,anxiety,depression,drug regimens,fluoxetine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要